Bristol Myers to purchase Karuna, maker of schizophrenia drug with huge potential

For Bristol, the purchase of Karuna represents a re-entry into the market for drugs to treat psychiatric and neurological diseases.

December 22, 2023 Check out STAT+

Sponsored By

Christine Kao/STAT 3 issues to watch in global health in 2024 Among the issues to watch are the campaign to eradicate polio, the effort to prepare for the next pandemic, and the impact of climate change. By Helen Branswell STAT+ | Venture capital is still pouring into drug research despite Medicare price negotiation Drug companies say Medicare drug price negotiation will discourage drug research investment, but that hasn't happened yet. By John Wilkerson STAT+ | Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion The centerpiece of the transaction, which values Karuna at $330 per share, is a drug called KarXT to treat schizophrenia. By Adam Feuerstein Courtesy Maria Kefalas Opinion: The unique pain and joy of celebrating Christmas with a child in the pediatric intensive care unit For families like mine, the pediatric intensive care unit can be something of a respite, especially during Christmas. By Maria Kefalas STAT+ | AAFP's CEO on how to keep primary care doctors in the field "Family medicine and primary care's obituary has been written many times in my 25-plus years of doing this work," said R. Shawn Martin, AAFP's CEO. By Brittany Trang STAT+ | FDA approves AstraZeneca, Ionis treatment for rare nerve disease The drug treats a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients' peripheral nerves. By Damian Garde Adobe STAT+ | FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear The label notes that some myeloma patients developed new cancers after treatment, but the agency notes no causal link has been found. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser